Hermann Einsele

73.6k total citations · 11 hit papers
761 papers, 29.8k citations indexed

About

Hermann Einsele is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Hermann Einsele has authored 761 papers receiving a total of 29.8k indexed citations (citations by other indexed papers that have themselves been cited), including 342 papers in Hematology, 324 papers in Oncology and 216 papers in Molecular Biology. Recurrent topics in Hermann Einsele's work include Multiple Myeloma Research and Treatments (247 papers), CAR-T cell therapy research (124 papers) and Antifungal resistance and susceptibility (108 papers). Hermann Einsele is often cited by papers focused on Multiple Myeloma Research and Treatments (247 papers), CAR-T cell therapy research (124 papers) and Antifungal resistance and susceptibility (108 papers). Hermann Einsele collaborates with scholars based in Germany, United States and France. Hermann Einsele's co-authors include Holger Hebart, Juergen Loeffler, Ulrike Schumacher, Jürgen Löffler, Michael Hudecek, Michael Boeckh, Per Ljungman, Jan Storek, Stefan Knop and Ralf C. Bargou and has published in prestigious journals such as Science, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Hermann Einsele

729 papers receiving 29.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

2009 1.1k citations Hermann Einsele et al. profile →
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

2008 798 citations Stefan Knop, Hermann Einsele et al. profile →
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Hermann Einsele et al. Blood profile →
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

2006 535 citations Hermann Einsele et al. Journal of Clinical Oncology profile →
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 518 citations Philippe Moreau, Pieter Sonneveld et al. profile →
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

2014 488 citations Max S. Topp, Hermann Einsele et al. Journal of Clinical Oncology profile →
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2021 460 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

2019 379 citations Justus Weber, Hermann Einsele et al. profile →
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

2020 233 citations Johannes Duell, Philippe Moreau et al. Journal of Clinical Oncology profile →
Therapeutic advances of targeting receptor tyrosine kinases in cancer

2024 80 citations Ciprian Tomuleasa, Adrian Bogdan Țigu et al. Signal Transduction and Targeted Therapy profile →
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

2023 77 citations Noopur Raje, Kenneth C. Anderson et al. Blood Cancer Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Hermann Einsele	12.7k	8.8k	8.4k	6.9k	6.2k	761	29.8k
Tsutomu Takeuchi	3.7k 0.3×	3.7k 0.4×	4.8k 0.6×	4.5k 0.6×	2.5k 0.4×	1.2k	30.6k
Per Ljungman	8.9k 0.7×	13.5k 1.5×	11.6k 1.4×	1.7k 0.2×	5.2k 0.8×	489	29.3k
Richard E. Champlin	14.9k 1.2×	5.2k 0.6×	27.2k 3.2×	6.7k 1.0×	2.0k 0.3×	1.1k	45.3k
Daniel J. Weisdorf	11.4k 0.9×	4.0k 0.5×	24.2k 2.9×	5.1k 0.7×	1.6k 0.2×	732	38.4k
Gèrard Socié	7.4k 0.6×	3.6k 0.4×	18.7k 2.2×	3.4k 0.5×	1.5k 0.2×	701	30.2k
Thomas E. Starzl	6.7k 0.5×	12.7k 1.4×	2.7k 0.3×	4.6k 0.7×	2.4k 0.4×	1.3k	56.9k
Dorothy H. Crawford	6.0k 0.5×	5.7k 0.6×	2.4k 0.3×	3.0k 0.4×	2.6k 0.4×	318	17.4k
Paul J. Martin	6.9k 0.5×	3.2k 0.4×	20.5k 2.4×	3.3k 0.5×	1.5k 0.2×	568	34.2k
Daniel C. Douek	6.1k 0.5×	9.5k 1.1×	2.5k 0.3×	6.2k 0.9×	11.1k 1.8×	338	44.9k
John J. Fung	5.4k 0.4×	10.6k 1.2×	1.6k 0.2×	4.3k 0.6×	2.8k 0.5×	1.2k	44.3k

Countries citing papers authored by Hermann Einsele

Since Specialization

Citations

This map shows the geographic impact of Hermann Einsele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hermann Einsele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hermann Einsele more than expected).

Fields of papers citing papers by Hermann Einsele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hermann Einsele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hermann Einsele. The network helps show where Hermann Einsele may publish in the future.

Co-authorship network of co-authors of Hermann Einsele

This figure shows the co-authorship network connecting the top 25 collaborators of Hermann Einsele. A scholar is included among the top collaborators of Hermann Einsele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hermann Einsele. Hermann Einsele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kurzai, Oliver, Arnhild Grothey, Lars Dölken, et al.. (2025). Unveiling immune interference: how the dendritic cell response to co-infection with Aspergillus fumigatus is modulated by human cytomegalovirus and its virokine _CMV IL-10. mBio. 16(11). e0154125–e0154125. 1 indexed citations

Frantz, Stefan, et al.. (2024). Needs of amyloidosis patients and their care providers: design & first results of the AMY-NEEDS research and care program. Orphanet Journal of Rare Diseases. 19(1). 58–58. 2 indexed citations

Leypoldt, Lisa, Xiang Zhou, Winfried Alsdorf, et al.. (2024). Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement. Blood. 144(Supplement 1). 3792.4–3792.4.

Tomuleasa, Ciprian, Adrian Bogdan Țigu, Raluca Munteanu, et al.. (2024). Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduction and Targeted Therapy. 9(1). 201–201. 80 indexed citations breakdown →

Danhof, Sophia, Xiang Zhou, Georg Fette, et al.. (2024). Real-World Confirmatory Analysis of the Current IMWG Diagnostic Criteria Identifies Early Transformation As Major Risk Factor in Plasma Cell Leukemia. Blood. 144(Supplement 1). 6893–6893.

Arnulf, Bertrand, Tessa Kerre, Mounzer Agha, et al.. (2024). Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.. Journal of Clinical Oncology. 42(16_suppl). 7505–7505. 2 indexed citations

Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502. 9 indexed citations

Vogt, Cornelia, Larissa Haertle, Xiang Zhou, et al.. (2023). Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells. Blood. 142(Supplement 1). 451–451. 2 indexed citations

Raje, Noopur, Kenneth C. Anderson, Hermann Einsele, et al.. (2023). Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer Journal. 13(1). 116–116. 77 indexed citations breakdown →

10.

Einsele, Hermann, Niels W.C.J. van de Donk, Bertrand Arnulf, et al.. (2021). CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S433–S434.

11.

Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398. 2 indexed citations

12.

Constantinescu, Cătălin, Sergiu Paşca, Alina‐Andreea Zimța, et al.. (2020). Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies. Journal of Clinical Medicine. 9(9). 2903–2903. 1 indexed citations

13.

Ataide, Marco A., Konrad Knöpper, Annika E. Peters, et al.. (2020). BATF3 programs CD8+ T cell memory. Nature Immunology. 21(11). 1397–1407. 88 indexed citations

14.

Danhof, Sophia, Martin Schreder, Antonio Giovanni Solimando, et al.. (2019). Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research. Journal of Clinical Medicine. 8(7). 999–999. 8 indexed citations

15.

Springer, Jan, P. Lewis White, Johanna Kessel, et al.. (2017). A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. Journal of Clinical Microbiology. 56(2). 30 indexed citations

16.

Rasche, Leo, Emmanuelle Ménoret, Valentina Dubljevic, et al.. (2016). A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement. Clinical Cancer Research. 22(17). 4341–4349. 47 indexed citations

17.

Danhof, Sophia, Martin Schreder, Leo Rasche, et al.. (2015). ‘Real‐life’ experience of preapproval carfilzomib‐based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. European Journal Of Haematology. 97(1). 25–32. 62 indexed citations

18.

Avota, Elita, et al.. (2011). Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood. 118(26). 6772–6782. 106 indexed citations

19.

Roll, Petra, Khalid Muhammad, Stefan Kleinert, et al.. (2011). In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis & Rheumatism. 63(5). 1255–1264. 78 indexed citations

20.

Wooldridge, Linda, Matthew Clement, Angharad E. Fenton-May, et al.. (2008). Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib. Clinical Cancer Research. 14(8). 2484–2491. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact